ProcellCure

ProcellCure is a South Korean biotechnology company dedicated to developing next-generation Natural Killer (NK) cell therapies for the treatment of various cancers. Led by industry veteran Lee Jong-wook, the company utilizes a proprietary platform designed for the high-purity expansion and potent activation of NK cells, aiming to overcome common hurdles in cell therapy such as limited persistence and poor infiltration into solid tumors. Their pipeline includes both unmodified NK cell therapies and Chimeric Antigen Receptor (CAR)-NK programs targeting solid tumors and hematologic malignancies. ProcellCure focuses on establishing a robust manufacturing process to ensure the scalability and efficacy of its off-the-shelf allogeneic cell products. The company has successfully secured significant venture capital funding to advance its lead candidates toward clinical trials.